Profit

Generic Nexium to Boost Dr Reddy's Bottlomline: Surjit Pal

PUBLISHED ON: September 28, 2015 | Duration: 10 min, 31 sec

facebooktwitteremailkoo
loading..
Surjit Pal, pharma analyst at Prabhudas Lilladher, told NDTV that Dr Reddy's Lab may capture 10-12 per cent market share in Nexium generics in the US in a year, which may add Rs 12 to its annual earnings per share.
ALSO WATCH
Sensex Gains Over 50 Points, Nifty Near 10,930

................................ Advertisement ................................

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com